Cargando…
Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213742/ https://www.ncbi.nlm.nih.gov/pubmed/35756663 http://dx.doi.org/10.3389/fonc.2022.932637 |
_version_ | 1784730904076222464 |
---|---|
author | Yaney, Alexander Stevens, Andrew Monk, Paul Martin, Douglas Diaz, Dayssy A. Wang, Shang-Jui |
author_facet | Yaney, Alexander Stevens, Andrew Monk, Paul Martin, Douglas Diaz, Dayssy A. Wang, Shang-Jui |
author_sort | Yaney, Alexander |
collection | PubMed |
description | Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of de novo oligometastatic, oligorecurrent and oligoprogressive prostate cancer. |
format | Online Article Text |
id | pubmed-9213742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92137422022-06-23 Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review Yaney, Alexander Stevens, Andrew Monk, Paul Martin, Douglas Diaz, Dayssy A. Wang, Shang-Jui Front Oncol Oncology Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of de novo oligometastatic, oligorecurrent and oligoprogressive prostate cancer. Frontiers Media S.A. 2022-06-08 /pmc/articles/PMC9213742/ /pubmed/35756663 http://dx.doi.org/10.3389/fonc.2022.932637 Text en Copyright © 2022 Yaney, Stevens, Monk, Martin, Diaz and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yaney, Alexander Stevens, Andrew Monk, Paul Martin, Douglas Diaz, Dayssy A. Wang, Shang-Jui Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title | Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title_full | Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title_fullStr | Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title_full_unstemmed | Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title_short | Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review |
title_sort | radiotherapy in oligometastatic, oligorecurrent and oligoprogressive prostate cancer: a mini-review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213742/ https://www.ncbi.nlm.nih.gov/pubmed/35756663 http://dx.doi.org/10.3389/fonc.2022.932637 |
work_keys_str_mv | AT yaneyalexander radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview AT stevensandrew radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview AT monkpaul radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview AT martindouglas radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview AT diazdayssya radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview AT wangshangjui radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview |